The Gut Microbiome and Aging: Microbial Regulation of Healthspan and Longevity

1. Introduction: The Microbiome as a Modifiable Input to Aging Biology

The adult human body carries an estimated 3.8 × 10¹³ bacterial cells, a population of the same order of magnitude as the number of human cells, with the great majority residing in the colon (Sender et al., 2016). Metagenomic sequencing of the gut community has catalogued on the order of 3.3 million non-redundant microbial genes — roughly 150-fold larger than the human gene complement (Qin et al., 2010). This collective genome encodes functions the host does not perform itself: fermentation of dietary fibre into short-chain fatty acids, biotransformation of bile acids and drugs, synthesis of certain vitamins and amino acids, and the generation of a large repertoire of small molecules that enter the portal and systemic circulation.

Because several of these functions intersect with processes that deteriorate with age — immune regulation, mucosal barrier integrity, glucose and lipid handling, and neuroinflammation — the gut microbiome has become a central candidate for a modifiable determinant of healthspan. The hypothesis is attractive: unlike the genome, the microbiome can be reshaped by diet, drugs, and live microbial products. But the strength of the evidence varies enormously across claims. Many widely repeated conclusions rest on cross-sectional human cohorts, in which the microbiome is associated with age, frailty, or disease without establishing direction of effect. Stronger causal evidence comes from animal models using germ-free animals, antibiotic perturbation, and heterochronic faecal transplantation — systems that isolate microbial contributions but do not automatically translate to humans.

This article examines four things in turn: how the intestinal community changes across the lifespan; the molecular pathways that plausibly link it to recognised hallmarks of aging; the hierarchy of evidence separating correlation from causation; and what interventions have actually been shown to do in people. Throughout, a distinction is maintained between established findings (replicated, with mechanistic support), emerging findings (consistent but limited in scope or model system), and hypotheses (plausible but unproven).

2. Composition and Function of the Gut Microbiome Across the Lifespan

2.1. Ecological and Functional Principles

Two terms are frequently conflated. The microbiota is the assemblage of microorganisms; the microbiome is that community together with its collective genomes and the surrounding habitat. The distinction matters because taxonomic composition and functional capacity are only partially coupled. Many gut functions are encoded by multiple, unrelated taxa, a property known as functional redundancy. As a result, a shift in which species are present need not imply a loss of the metabolic functions they perform, and conversely, a stable taxonomic profile can conceal functional change.

Three further ecological properties frame age-related findings. First, adult gut communities are highly individual: inter-person variation is large relative to the differences typically reported between age groups, which is one reason age-microbiome associations are difficult to replicate. Second, the community is resilient to short-term perturbation but can cross into alternative stable states after repeated disturbance, such as courses of antibiotics. Third, the gut is an open ecosystem: diet, medication, infection, physical activity, and host immunity all act on it continuously, so any observed association with age is entangled with these exposures.

2.2. Age-Associated Shifts in Composition and Function

Across the lifespan the gut community is not static. Cross-sectional and longitudinal studies describe a gradual trajectory rather than a discrete threshold: there is no age at which the microbiota abruptly changes, but rather a slow drift beginning in adulthood (O’Toole & Jeffery, 2015). Commonly reported features of older adults include a decline in strict anaerobes that produce short-chain fatty acids — notably Faecalibacterium prausnitzii, Roseburia, and other Clostridia cluster IV/XIVa members — alongside an expansion of facultative anaerobes and potential pathogens, particularly within the Proteobacteria. Aged communities also tend to show greater inter-individual divergence and reduced temporal stability.

These compositional changes correlate with clinically relevant phenotypes. In a cohort of 178 older people, faecal microbiota composition clustered by residence setting and habitual diet, and the separation correlated with frailty, co-morbidity, nutritional status, and circulating inflammatory markers; long-stay residential care was associated with lower diversity (Claesson et al., 2012). A large multi-cohort analysis of more than 9,000 individuals found that microbiomes become increasingly unique to each person with age, and that continued divergence — together with loss of the core genus Bacteroides — tracked with healthier aging and predicted survival over a four-year follow-up (Wilmanski et al., 2021).

These are associations. Older age is accompanied by changes in diet, dentition, polypharmacy (including proton-pump inhibitors and antibiotics), physical activity, immune status, and co-morbidity, any of which can reshape the microbiota independently of aging per se. Cohorts also differ by geography and methodology, and age-linked microbial signatures are only partly reproducible across studies. The honest summary is that the aged gut microbiome is distinct but variable, and that the strongest consistent signal is functional — a reduced capacity for fibre fermentation and short-chain fatty acid production — rather than any single diagnostic taxon.

2.3. Centenarians and the Elusive Longevity Microbiome

Exceptionally long-lived individuals have been studied as a natural experiment in healthy aging. Early work found that centenarians have a distinct community with reduced Faecalibacterium prausnitzii and shifts within Firmicutes, changes that correlated with higher circulating inflammatory markers rather than with an obviously anti-inflammatory profile (Biagi et al., 2010). This is an important corrective to the expectation that longevity is simply «a young microbiome preserved.»

A more recent finding identified a potentially mechanistically interesting feature. The microbiome of centenarians is enriched in bacteria capable of producing unusual secondary bile acids, including isoallolithocholic acid (isoalloLCA). Strains of the family Odoribacteraceae were shown to synthesise isoalloLCA via the enzymes 5α-reductase and 3β-hydroxysteroid dehydrogenase, and isoalloLCA exerted potent antimicrobial activity against Gram-positive multidrug-resistant pathogens such as Clostridioides difficile and Enterococcus faecium (Sato et al., 2021). The proposed interpretation is that such metabolites help restrain pathobionts and thereby contribute to intestinal homeostasis. This is emerging evidence: it links a specific bacterial metabolite to a concrete biological activity, but it does not establish that this bile-acid pathway causes human longevity, and centenarian cohorts from different regions do not share a single, uniform microbial signature.

3. Mechanistic Pathways Linking the Microbiome to Aging Hallmarks

Several molecular routes connect microbial metabolism to processes recognised as hallmarks of aging, including chronic low-grade inflammation («inflammaging»), immunosenescence, metabolic dysregulation, and impaired proteostasis. The pathways below are ordered from the best established to the more hypothesis-driven.

3.1. Short-Chain Fatty Acids and Immune Regulation

Microbial fermentation of dietary fibre yields acetate, propionate, and butyrate. Butyrate is the principal energy source for colonic epithelial cells and a potent modulator of immunity. In mice, butyrate promotes the differentiation of colonic regulatory T cells through inhibition of histone deacetylases and increased acetylation at the Foxp3 locus, and ameliorates experimental colitis (Furusawa et al., 2013). Short-chain fatty acids also signal through G-protein-coupled receptors such as FFAR2 and FFAR3, influencing neutrophil function, gut hormone release, and epithelial integrity. Because regulatory T cells restrain inflammatory signalling, a decline in short-chain fatty acid supply is a plausible contributor to the pro-inflammatory drift of the aging immune system. This mechanism is well supported mechanistically but has been demonstrated most rigorously in animal and in vitro systems.

3.2. Gut Barrier Integrity, Endotoxemia, and Inflammaging

An intact intestinal barrier restricts the translocation of microbial components such as lipopolysaccharide into the circulation. In mice, intestinal permeability increases with age in a microbiota-dependent manner: germ-free animals were protected from the age-related rise in circulating inflammatory cytokines, and age-associated microbiota changes were attenuated in tumour necrosis factor (TNF)-deficient animals, while co-housing germ-free mice with old (but not young) animals raised systemic cytokines (Thevaranjan et al., 2017). This study also found that a higher proportion of germ-free mice reached 600 days than conventional controls, an observation that should be read as model-specific rather than as evidence for a general longevity effect.

Whether an analogous «leaky gut» drives inflammaging in humans is more uncertain. Intestinal permeability is difficult to measure reliably in people, and the correlations among permeability, microbial translocation, and chronic disease are inconsistent. The pathway is mechanistically coherent and well supported in rodents, but its quantitative contribution to human aging remains unresolved.

3.3. Bile Acids as Host Signalling Molecules

The liver synthesises primary bile acids (cholate and chenodeoxycholate), which gut bacteria deconjugate and, in some cases, 7α-dehydroxylate to secondary bile acids such as deoxycholate and lithocholate. These molecules are not merely detergents: they are ligands for the nuclear receptor FXR and the membrane receptor TGR5, which regulate bile-acid synthesis, glucose and lipid metabolism, energy expenditure, and immune tone. Because the microbiome determines the size and composition of the bile-acid pool, it indirectly tunes these host receptors. The centenarian isoalloLCA finding (Section 2.3) sits within this framework. As with barrier integrity, the individual components are established, but how much the bile-acid axis contributes to human aging phenotypes is not resolved.

3.4. Tryptophan Metabolites and Aryl Hydrocarbon Receptor Signalling

Gut bacteria convert dietary tryptophan into indole and indole derivatives, including indole-3-aldehyde and indole-3-propionate. These compounds activate the aryl hydrocarbon receptor (AhR) in intestinal epithelial and immune cells, promoting interleukin-22 production, reinforcing barrier function, and supporting immune homeostasis. Disturbance of this axis is associated with inflammatory conditions. The mechanism is well characterised in animal models and provides a plausible link between loss of proteolytic and saccharolytic microbial function in old age and declining mucosal defence, though direct evidence for its role in human aging is indirect.

3.5. Trimethylamine N-Oxide and Cardiometabolic Risk

Gut bacteria convert dietary choline and carnitine to trimethylamine, which the liver oxidises to trimethylamine N-oxide (TMAO). In a cohort of more than 4,000 patients undergoing coronary angiography, elevated plasma TMAO was associated with a higher three-year risk of major adverse cardiovascular events, and TMAO production was suppressed by broad-spectrum antibiotics, confirming its microbial dependence (Tang et al., 2013). This is a clear example of a microbially generated metabolite linked to a disease of aging. However, the association is observational, and whether TMAO is a causal mediator or a marker of other risk factors remains debated; alternative causal analyses have produced conflicting results.

3.6. The Gut-Brain Axis

The microbiota influences the central nervous system through microbial metabolites, immune signalling, and the vagus nerve. Germ-free mice show defects in microglial maturation and function, and short-chain fatty acids help regulate microglial homeostasis (Erny et al., 2015). Heterochronic faecal transplantation in mice provides stronger causal evidence: transferring aged donor microbiota into young animals accelerated neuroinflammation and retinal inflammation and impaired intestinal barrier integrity, whereas transferring young microbiota into aged animals reversed several of these changes (Parker et al., 2022; Boehme et al., 2021). A 2026 study traced age-associated memory decline in mice to a specific species, Parabacteroides goldsteinii, whose medium-chain fatty acid products activated GPR84 signalling on intestinal myeloid cells, impaired vagal afferent function, and reduced hippocampal activation; interventions including a targeted bacteriophage, GPR84 inhibition, and restoration of vagal activity improved memory in aged mice (Cox et al., 2026).

These results are striking and mechanistically detailed, but they are all in rodents. Cognitive aging in humans is multi-factorial, the translational distance is large, and no human intervention has yet been shown to slow cognitive decline by altering the microbiome.

3.7. Drug Metabolism and Pharmacomicrobiomics

The microbiome behaves as an accessory metabolic organ. It chemically modifies drugs and dietary compounds, with consequences for efficacy and toxicity. A randomised, double-blind study in treatment-naive type 2 diabetes found that metformin substantially altered the gut microbiome, and that transferring the post-treatment microbiota to germ-free mice improved glucose tolerance — evidence that part of metformin’s benefit may be microbially mediated (Wu et al., 2017). This pathway is bidirectional and clinically important: proton-pump inhibitors, antibiotics, and other common medications in older adults reshape the community, potentially amplifying or confounding age-related changes.

4. From Correlation to Causation: The Evidence Hierarchy

Claims about the aging microbiome are only as strong as the study designs behind them. The following hierarchy is useful for weighing them.

1. Cross-sectional human cohorts. Inexpensive and hypothesis-generating, but vulnerable to confounding and reverse causation: disease, medication, and diet alter the microbiome, so an association with age may reflect neither aging nor causality.
2. Longitudinal human cohorts. Allow temporal ordering and stability to be assessed, but cannot isolate the microbiome from co-variables.
3. Germ-free and gnotobiotic animals. Establish necessity, but germ-free rearing alters immune and metabolic development, so phenotypes are not simply «no microbiome.» They are powerful for mechanism, not for magnitude in normal hosts.
4. Antibiotic perturbation and recolonisation. Demonstrate reversibility, but broad-spectrum antibiotics also remove metabolites crucial to colonocytes and permit pathogen expansion, complicating interpretation.
5. Heterochronic faecal transplantation in animals. The strongest current causal evidence for aging phenotypes; transfer of aged microbiota accelerates, and young microbiota partially reverses, features of aging in mice. Still a different species with a different lifespan architecture.
6. Human randomised trials. The only design that can demonstrate benefit in people for a defined intervention. Human faecal transplantation is proven only for recurrent Clostridioides difficile infection, and dietary and probiotic trials show modest, often strain- or context-specific effects.

Mendelian randomisation, which uses genetic variants as instruments, has been applied to microbiome traits, but gut microbial features are influenced by many weak genetic effects and by the environment, so instrument strength is generally low; such studies are suggestive rather than decisive. The recurring error in this field is to present an animal causal result as if it applied to human aging, or to present a human association as if it were causal.

5. Interventions: What Has Been Shown, and How Strongly

5.1. Diet and Dietary Fibre

Diet is the most reproducible lever on the gut microbiome in humans. In a 17-week randomised study, one group increased plant-based fibre while another increased fermented foods. The high-fibre arm did not increase microbial diversity, but did increase microbial carbohydrate-active enzymes and elicited individualised immune responses that corresponded to baseline diversity. The high-fermented-food arm steadily increased microbiota diversity and decreased markers of inflammation (Wastyk et al., 2021). Mediterranean-style dietary patterns are also associated with more favourable microbial and inflammatory profiles in older adults, though much of this evidence is observational. The practical message is that fibre changes what the existing community does, whereas some dietary interventions can shift who is present — and that responses are highly individual.

5.2. Probiotics and Defined Consortia

The term «probiotic» has a precise definition: live microorganisms that, when administered in adequate amounts, confer a health benefit on the host (Hill et al., 2014). Effects are strain- and host-specific; benefits documented for one product do not generalise. In older adults, single- or multi-strain probiotics show modest, inconsistent effects on immune markers, bowel habit, and infectious outcomes. Colonisation is variable and often transient, and the introduced strains may not persist against a resilient resident community.

5.3. Next-Generation Microbes: Akkermansia muciniphila

Akkermansia muciniphila is a mucin-degrading resident that is consistently associated with metabolic health. In a proof-of-concept, double-blind, placebo-controlled trial of 32 overweight or obese insulin-resistant volunteers, three months of oral pasteurised A. muciniphila improved insulin sensitivity (a reported ~29% improvement relative to placebo), reduced insulinemia and total cholesterol, and lowered some liver-injury and inflammation markers, without evidently reshaping overall microbiome structure (Depommier et al., 2019). This was a small single-centre pilot, and these results require replication at scale; a subsequent larger multicentre randomised trial (NCT05114018) reported only a small, statistically non-significant improvement in whole-body insulin sensitivity, with possible benefits concentrated in participants with low baseline Akkermansia levels. Baseline microbiota status may therefore determine who responds.

5.4. Prebiotics, Postbiotics, and Synbiotics

Prebiotics are substrates selectively used by host microorganisms to confer a health benefit; most require oral doses on the order of several grams per day to have measurable effects. Postbiotics (non-viable microbial preparations and their products) and synbiotics (combined pro- and prebiotics) are active research areas. Evidence in older adults is limited and effect sizes are generally small.

5.5. Faecal Microbiota Transplantation

Faecal microbiota transplantation (FMT) is an established therapy for recurrent Clostridioides difficile infection: in a landmark randomised trial, duodenal infusion of donor faeces cured 15 of 16 patients overall, versus roughly a quarter to a third with vancomycin alone (van Nood et al., 2013). This is the one setting where microbial transfer has a large, reproducible clinical effect, and it works by restoring colonisation resistance against a specific pathogen.

Applying FMT to aging is a different proposition. In aged animals, young-donor FMT improves markers of intestinal, immune, and neurological function, but no human trial has demonstrated health or lifespan benefits from FMT for aging. Human FMT also carries real risks — transmission of pathogens, and of conditions linked to donor microbiota — which is why regulators restrict it largely to C. difficile and to research protocols. It should not be presented as a rejuvenation therapy.

5.6. Pharmacological and Environmental Levers

Some of the most powerful influences on the aging microbiome are not supplements. Appropriate deprescribing of unnecessary proton-pump inhibitors and antibiotics, management of constipation and dentition, and physical activity all affect the community. Metformin both alters the microbiome and appears to act partly through it (Wu et al., 2017), making it a model for drugs whose geroprotective effects, if any, may be partly microbially mediated.

6. Can the Microbiome Extend Lifespan?

In mice, the evidence for a causal role in healthspan — and in some models lifespan — is now substantial. Heterochronic FMT transfers aging- and youth-associated phenotypes between animals; aged animals that receive young microbiota show improved intestinal barrier function, immune homeostasis, metabolic profile, frailty scores, and neurobehavioural outcomes (Parker et al., 2022; Boehme et al., 2021). Germ-free mice in one study were protected from age-related inflammation and showed improved early survival relative to conventional controls (Thevaranjan et al., 2017). In progeroid and invertebrate models, microbiota manipulation has been reported to alter healthspan and, in some cases, lifespan.

None of this establishes a human lifespan effect. The evidence in people consists of associations between microbiome features and survival (Wilmanski et al., 2021) and of interventions that modify intermediate risk factors such as insulin sensitivity and inflammation. The realistic near-term contribution of microbiome-directed strategies is therefore through reducing the burden of cardiometabolic and infectious disease — conditions that compress the healthy years — rather than through any proven extension of maximum lifespan. Claims of a «longevity gut» that confers added years should be treated as unproven.

7. Limitations and Open Questions

• Confounding and reverse causation. Diet, drugs, comorbidity, and residence all shape the microbiome, so age associations are difficult to isolate.
• Cross-sectional designs dominate. Most human data cannot establish temporal order, let alone causation.
• Poor reproducibility across cohorts. The same phenotype yields different taxa in different studies, partly because of geography, diet, and methodology.
• Functional redundancy. Taxonomic markers may not map to the functions that matter, making mechanism harder to identify.
• Model-to-human translation. Germ-free and FMT rodent experiments are mechanistically powerful but may not predict human responses.
• Heterogeneous and often small effect sizes. Interventions rarely produce large, uniform changes, and responders are often not predictable in advance.
• Safety. Live microbial products and FMT carry infection and off-target risks that are especially relevant in frail older adults.
• Ethics and commerce. The market for microbiome-based longevity products outpaces the evidence, creating pressure to overstate findings.

8. Future Directions

Longitudinal cohorts with dense sampling. Tracking individuals over years, with standardised collection protocols, is necessary to separate aging effects from co-variables and to identify within-person trajectories.

Function-first readouts. Metabolomic and metagenomic functional profiling, rather than taxonomy alone, is more likely to identify mechanisms and to yield reproducible biomarkers.

Predictive responders and stratified trials. The Akkermansia data suggest that baseline microbiome status may predict benefit. Interventional trials should pre-specify subgroup analyses based on baseline composition.

Defined consortia and precision tools. Rather than undefined faecal material, defined bacterial consortia, engineered live biotherapeutics, and even bacteriophages (as in the 2026 P. goldsteinii work) offer more controllable, targeted interventions.

Causal inference. Combining randomised trials, longitudinal cohorts, and careful instrumental analyses will be required to move from association to actionable causal claims in humans.

9. Conclusion

The gut microbiome is a genuine and potentially modifiable contributor to the biology of aging. Its age-related drift is characterised less by a single «bad» species than by a decline in fibre-fermenting capacity, a loss of community stability, and an expansion of potentially inflammatory taxa and their products. Mechanistically, short-chain fatty acids, bile-acid signalling, tryptophan metabolites, barrier integrity, and gut-brain communication provide credible routes by which these changes could influence inflammation, metabolism, and cognition. The strongest causal evidence comes from animal systems in which the microbiome can be swapped or removed; the human evidence is dominated by associations, plus a handful of small randomised trials showing real but modest and heterogeneous effects.

The defensible position is therefore neither dismissal nor enthusiasm, but precision. Fibre-rich and fermented-food diets are low-risk and plausibly beneficial. Specific microbial products such as Akkermansia muciniphila are promising but unproven at scale. Faecal transplantation is a proven therapy for one infection and an experimental strategy for aging. Microbiome rejuvenation as an anti-aging intervention in humans remains a research goal, not an established treatment — and the fastest route to reducing the disease burden of old age is likely to be through its metabolic and cardiovascular effects rather than through any single «longevity microbe.»

Sources and Key Research Centers

1. Qin J et al. «A human gut microbial gene catalogue established by metagenomic sequencing.» Nature, 2010; 464(7285): 59-65. DOI: 10.1038/nature08821
2. Sender R, Fuchs S, Milo R. «Revised estimates for the number of human and bacteria cells in the body.» PLOS Biology, 2016; 14(8): e1002533. DOI: 10.1371/journal.pbio.1002533
3. Lynch SV, Pedersen O. «The human intestinal microbiome in health and disease.» New England Journal of Medicine, 2016; 375: 2369-2379. DOI: 10.1056/NEJMra1600266
4. O’Toole PW, Jeffery IB. «Gut microbiota and aging.» Science, 2015; 350(6265): 1214-1215. DOI: 10.1126/science.aac8469
5. Claesson MJ et al. «Gut microbiota composition correlates with diet and health in the elderly.» Nature, 2012; 488(7410): 178-184. DOI: 10.1038/nature11319
6. Biagi E et al. «Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians.» PLOS ONE, 2010; 5(5): e10667. DOI: 10.1371/journal.pone.0010667
7. Odamaki T et al. «Age-related changes in gut microbiota composition from newborn to centenarian: a cross-sectional study.» BMC Microbiology, 2016; 16: 90. DOI: 10.1186/s12866-016-0708-5
8. Ghosh TS, Shanahan F, O’Toole PW. «The gut microbiome as a modulator of healthy ageing.» Nature Reviews Gastroenterology & Hepatology, 2022; 19(9): 565-584. DOI: 10.1038/s41575-022-00605-x
9. Wilmanski T et al. «Gut microbiome pattern reflects healthy ageing and predicts survival in humans.» Nature Metabolism, 2021; 3(2): 274-286. DOI: 10.1038/s42255-021-00348-0
10. Sato Y et al. «Novel bile acid biosynthetic pathways are enriched in the microbiome of centenarians.» Nature, 2021; 599(7885): 458-464. DOI: 10.1038/s41586-021-03832-5
11. Furusawa Y et al. «Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells.» Nature, 2013; 504(7480): 446-450. DOI: 10.1038/nature12721
12. Thevaranjan N et al. «Age-associated microbial dysbiosis promotes intestinal permeability, systemic inflammation, and macrophage dysfunction.» Cell Host & Microbe, 2017; 21(4): 455-466. DOI: 10.1016/j.chom.2017.03.002
13. Erny D et al. «Host microbiota constantly control maturation and function of microglia in the CNS.» Nature Neuroscience, 2015; 18(7): 965-977. DOI: 10.1038/nn.4030
14. Tang WHW et al. «Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.» New England Journal of Medicine, 2013; 368(17): 1575-1584. DOI: 10.1056/NEJMoa1109400
15. Wu H et al. «Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug.» Nature Medicine, 2017; 23(7): 850-858. DOI: 10.1038/nm.4345
16. Wastyk HC et al. «Gut-microbiota-targeted diets modulate human immune status.» Cell, 2021; 184(16): 4137-4153. DOI: 10.1016/j.cell.2021.06.019
17. Depommier C et al. «Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study.» Nature Medicine, 2019; 25(7): 1096-1103. DOI: 10.1038/s41591-019-0495-2
18. Hill C et al. «The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic.» Nature Reviews Gastroenterology & Hepatology, 2014; 11(8): 506-514. DOI: 10.1038/nrgastro.2014.66
19. van Nood E et al. «Duodenal infusion of donor feces for recurrent Clostridium difficile.» New England Journal of Medicine, 2013; 368(5): 407-415. DOI: 10.1056/NEJMoa1205037
20. Parker A et al. «Fecal microbiota transfer between young and aged mice reverses hallmarks of the aging gut, eye, and brain.» Microbiome, 2022; 10: 68. DOI: 10.1186/s40168-022-01243-w
21. Boehme M et al. «Microbiota from young mice counteracts selective age-associated behavioral deficits.» Nature Aging, 2021; 1(8): 666-676. DOI: 10.1038/s43587-021-00093-9
22. Cox TO et al. «Intestinal interoceptive dysfunction drives age-associated cognitive decline.» Nature, 2026; 652(8109): 442-450. DOI: 10.1038/s41586-026-10191-6
23. NIH Human Microbiome Project (HMP) — reference catalogues and resources for the healthy human microbiome.
24. National Institute on Aging (NIA) — research programmes on the microbiome, inflammation, and aging biology.
25. APC Microbiome Ireland, University College Cork — ELDERMET and related work on diet, the microbiome, and ageing (O’Toole, Shanahan).
26. Quadram Institute, Norwich — heterochronic faecal transplantation and gut-brain/retina aging research (Carding, Parker).
27. RIKEN Center for Integrative Medical Sciences — centenarian microbiome and bile-acid research (Honda).
28. ClinicalTrials.gov — registered trials of probiotics, prebiotics, and microbiota interventions in older adults (search terms: microbiome aging, Akkermansia muciniphila, faecal microbiota transplantation).